ARIUS Research Inc.

ARIUS Research Inc. is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST™, that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline, which is used for commercial collaborations and in-house development. ARIUS has ongoing partnerships with key biotechnology and drug development companies. The company is listed on the TSX Venture Exchange under the symbol “ARI”.

Contact Details: 55 York Street, 16th Floor Toronto Ontario M5J 1R7 Canada Tel: (416) 862-2323 Fax: (416) 862-9696 Email: contact@ariusresearch.com WWW: www.ARIUSRESEARCH.COM/

Loading...

Press Releases on ARIUS Research Inc.:
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche	9th September, 2008	ARIUS Research Inc.	TORONTO, Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that RiskMetrics
Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics	23rd July, 2008	ARIUS Research Inc.	BASEL, Switzerland and TORONTO, July 23 /PRNewswire-FirstCall/ - Roche (SWX: ROG) and ARIUS Research Inc. (TSX:ARI) today announced that the two companies have signed a definitive agreement for Roche
ARIUS announces second quarter fiscal 2008 financial results	11th July, 2008	ARIUS Research Inc.	TORONTO, July 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial
OXFORD BIOMEDICA AND ARIUS RESEARCH EXTEND COLLABORATION ON NOVEL CANCER	1st October, 2004	Oxford Biomedica	OXFORD BIOMEDICA AND ARIUS RESEARCH EXTEND COLLABORATION ON NOVEL CANCER TARGETS Oxford , UK – 16 29 October 2004 : Oxford BioMedica (LSE: OXB) and ARIUS Research Inc. (TSX-VE: ARI)
ARIUS Research Inc. and Oxford BioMedica plc: collaboration attracts	1st October, 2002	Oxford Biomedica	ARIUS Research Inc. and Oxford BioMedica plc: collaboration attracts first development partner in Protein Design Labs Inc. Oxford,

ARIUS Research Inc. Patents:
US Patent No.	Title
7488475	Antibody therapy of tumors
7361342	Cancerous disease modifying antibodies
7348413	Cancerous disease modifying antibodies
7256272	Individualized anti-cancer antibodies
7256271	Cancerous disease modifying antibodies
→View more ARIUS Research Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 738 times since April 2007, the link to the organisation's website has been followed 132 times

Recent Search Terms used to find this page: Arius Research Inc | Arius genes | ARIUS Research Inc. ARI | arius research | arius research | biotech companies | Arius | Arius, Toronto | Arius, Toronto | arius | .

Search for more companies in Toronto

Search for more companies in Ontario

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ARIUS Research Inc.